North America Blood Brain Barrier Technologies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing Permeability, Passive Diffusion, and Other Non-Invasive BBB Technologies) and Application (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer, and Others)
Market Introduction
The North American blood brain barrier technologies consists of the US, Canada, and Mexico. The US is the largest market for North American blood brain barrier technologies. The United States blood brain barrier technologies market is estimated to be the largest in the region and is likely to continue its dominance during forecast years. The market across the country is expected to grow due to the well-established infrastructure, increasing prevalence of neurological diseases such as Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer. For instance, according to the American Society of Clinical Oncology (ASCO), in 2021, an estimated 24,530 adults (13,840 men and 10,690 women) will be diagnosed with primary cancerous tumors of the brain and spinal cord in the United States. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Market players are adopting organic and inorganic growth strategies for market development. For instance, in June 2021, The U.S. Food and Drug Administration (FDA) granted Eli Lilly and Company’s Breakthrough Technology designation for donanemab antibody therapy for Alzheimer's disease (AD). Thus, owing to the factors mentioned above, it is expected that the blood brain barrier technologies market is likely to propel exponentially during the forecast years. Similarly, In June 2021, U.S. Food and Drug Administration approved Pfizer’s Aduhelm (aducanumab) for the treatment of Alzheimer disease. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments Also, In October 2020, Bristol Myers Squibb announced that Health Canada approved ZEPOSIA (ozanimod) for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.
The worldwide impacts of COVID-19 are being felt across several markets. Although the healthcare sector has witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. New research published in December 2020 suggests COVID-19 can cross the blood-brain barrier. The finding gives credence to the many patients who complain of lingering cognitive side effects long after contracting the disease. The University of Washington School of Medicine researchers in Seattle led the study, which looked at how the coronavirus spike protein behaves in mice. This S1 protein, they found, can cross the blood-brain barrier and grab onto other cell receptors, which may be toxic to brain tissue.
Get more information on this report : 
Market Overview and Dynamics
The blood brain barrier technologies market in North America is expected to grow from US$ 391.56 million in 2021 to US$ 1,936.23 million by 2028; it is estimated to grow at a CAGR of 25.7% from 2021 to 2028. Efficient drug delivery to treat brain-related diseases is challenging. The reason is the barriers, such as the blood brain barrier, present in the central nervous system. The blood-brain barrier formed by the endothelial cells of the cerebral capillaries restricts the entry of most drugs and delivery systems. The blood-cerebrospinal fluid barrier and blood tumor barrier also present a massive problem for the effective delivery of therapeutics to the central nervous system (CNS). Therefore, market players are launching various techniques such as molecular trojan horse technology, biology-based approach, BBB disruption, stereotactically guided insertion, intranasal delivery, chemical methods, and transporter-mediated delivery to enhance the amount and concentration of therapeutic compounds in the brain. A few of the recent developments related to the blood-brain barrier technologies market have taken place in recent years. For instance, In January 2019, The US Food and Drug Administration (FDA) approved the first generic version of Sabril (vigabatrin) tablets, manufactured by US subsidiary of Teva Pharmaceutical Industries, for the treatment of complex partial seizures as add-on therapy in patients. Further, In June 2021, the US FDA granted breakthrough therapy designation for donanemab antibody therapy for Alzheimer's disease (AD) developed by Eli Lilly and Company. Thus, the active participation of market players in product innovation and development and increase in approvals of products are likely to fuel the market growth in the coming years
Key Market Segments
In terms of technology, the increasing permeability segment accounted for the largest share of the North America blood brain barrier technologies market in 2021. In terms of application, the parkinson’s disease segment accounted for the largest share of the North America blood brain barrier technologies market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the blood brain barrier technologies market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson & Johnson Services, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; and Bioasis Technologies, Inc. among others.
Reasons to buy report
- To understand the North America blood brain barrier technologies market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America blood brain barrier technologies market
- Efficiently plan M&A and partnership deals in North America blood brain barrier technologies market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America blood brain barrier technologies market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Blood Brain Barrier Technologies Market Segmentation
North America Blood Brain Barrier Technologies Market – By Technology
- Bispecific Antibody RMT Approach
- Trojan Horse Approach
- Increasing Permeability
- Passive Diffusion
- Other Non-Invasive BBB Technologies
North America Blood Brain Barrier Technologies Market – By Application
- Alzheimer’s Disease
- Epilepsy
- Parkinson’s Disease
- Multiple Sclerosis
- Hunter’s Syndrome
- Brain Cancer
- Others
North America Blood Brain Barrier Technologies Market – By Country
- US
- Canada
- Mexico
North America Blood Brain Barrier Technologies Market – Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Fabre-Kramer Pharmaceuticals, Inc.
- Bioasis Technologies, Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Blood Brain Barrier Technologies Market – By Technology
1.3.2 North America Blood Brain Barrier Technologies Market – By Application
1.3.3 North America Blood Brain Barrier Technologies Market– By Country
2. North America Blood Brain Barrier Technologies Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Blood Brain Barrier Technologies Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. North America Blood Brain Barrier Technologies Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Raising Prevalence of Neurological Disorders
5.1.2 Growing Geriatric Population and Rising Prevalence of Age-Associated Neurological Disorders
5.2 Market Restraints
5.2.1 Issues in Brain Medication Delivery
5.3 Market Opportunities
5.3.1 Vast Number of Product Approvals and Launches
5.4 Future Trends
5.4.1 Raising Demand of Nanoparticles for Brain Drug Delivery
5.5 Impact Analysis
6. North America Blood Brain Barrier Technologies – Market Analysis
6.1 North America Blood Brain Barrier Technologies Market Revenue Forecast and Analysis
7. North America Blood Brain Barrier Technologies Market Analysis – by Technology
7.1 Overview
7.2 Blood Brain Barrier Technologies Market, by Technology 2021 & 2028 (%)
7.3 Bispecific Antibody RMT Approach
7.3.1 Overview
7.3.2 Bispecific Antibody RMT Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Trojan Horse Approach
7.4.1 Overview
7.4.2 Trojan Horse Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Increasing Permeability
7.5.1 Overview
7.5.2 Increasing Permeability: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Passive Diffusion
7.6.1 Overview
7.6.2 Passive Diffusion: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Other Non-Invasive BBB Technologies
7.7.1 Overview
7.7.2 Other Non-Invasive BBB Technologies: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Blood Brain Barrier Technologies Market Analysis – By Application
8.1 Overview
8.2 Blood Brain Barrier Technologies Market, by Application 2021 & 2028 (%)
8.3 Alzheimer’s Disease
8.3.1 Overview
8.3.2 Alzheimer’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Epilepsy
8.4.1 Overview
8.4.2 Epilepsy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Parkinson’s Disease
8.5.1 Overview
8.5.2 Parkinson’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Multiple Sclerosis
8.6.1 Overview
8.6.2 Multiple Sclerosis: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Hunter’s Syndrome
8.7.1 Overview
8.7.2 Hunter’s Syndrome: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Brain Cancer
8.8.1 Overview
8.8.2 Brain Cancer: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Others
8.9.1 Overview
8.9.2 Others: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Blood Brain Barrier Technologies Market – Country Analysis
9.1 Overview
9.1.1 North America: Blood Brain Barrier Technologies Market, by Country, 2021 & 2028 (%)
9.1.1.1 US: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.1 US: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.2 US Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.3 US Blood Brain Barrier Technologies Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.1.2 Canada: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.1 Canada: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.2 Canada Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.3 Canada Blood Brain Barrier Technologies Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.1.3 Mexico: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.1 Mexico: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.2 Mexico Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.3 Mexico Blood Brain Barrier Technologies Market, by Application– Revenue and Forecast to 2028 (USD Million)
10. Impact Of COVID-19 Pandemic on North America Blood Brain Barrier Technologies Market
10.1 Impact Assessment of COVID-19 Pandemic
11. North America Blood Brain Barrier Technologies Market– Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Teva Pharmaceutical Industries Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Eli Lilly and Company
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bristol-Myers Squibb Company
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Pfizer, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Johnson and Johnson Services, Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Fabre-Kramer Pharmaceuticals, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Bioasis Technologies, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Blood Brain Barrier Technologies Market – Revenue, and Forecast to 2028 (US$ Million)
Table 2. US Blood Brain Barrier Technologies Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 3. US Blood Brain Barrier Technologies Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 4. Canada Blood Brain Barrier Technologies Market, by Technology -Revenue and Forecast to 2028 (USD Million)
Table 5. Canada Blood Brain Barrier Technologies Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 6. Mexico Blood Brain Barrier Technologies Market, by Technology -Revenue and Forecast to 2028 (USD Million)
Table 7. Mexico Blood Brain Barrier Technologies Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 8. Organic Developments Done By Companies
Table 9. Inorganic Developments Done By Companies
Table 10. Glossary of Terms, Blood Brain Barrier Technologies Market
LIST OF FIGURES
Figure 1. North America Blood Brain Barrier Technologies Market Segmentation
Figure 2. North America Blood Brain Barrier Technologies Market Segmentation, By Country
Figure 3. North America Blood Brain Barrier Technologies Market Overview
Figure 4. Increasing Permeability Segment Held the Largest Share by Technology in Blood Brain Barrier Technologies Market
Figure 5. U.S. to Show Significant Growth During Forecast Period
Figure 6. North America Blood Brain Barrier Technologies Market, Industry Landscape
Figure 7. North America PEST Analysis
Figure 8. North America Blood Brain Barrier Technologies Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 9. Blood Brain Barrier Technologies Market, by Technology 2021 & 2028 (%)
Figure 10. Bispecific Antibody RMT Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Trojan Horse Approach: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Increasing Permeability: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Passive Diffusion: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Other Non-Invasive BBB Technologies: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Blood Brain Barrier Technologies Market, by Application 2021 & 2028 (%)
Figure 16. Alzheimer’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Epilepsy: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Parkinson’s Disease: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Multiple Sclerosis: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Hunter’s Syndrome: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Brain Cancer: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America: Blood Brain Barrier Technologies Market, by Key Country – Revenue (2021) (USD Million)
Figure 24. North America: Blood Brain Barrier Technologies Market, by Country, 2021 & 2028 (%)
Figure 25. US: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 26. Canada: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 27. Mexico: Blood Brain Barrier Technologies Market – Revenue and Forecast to 2028 (USD Million)
Figure 28. Impact of COVID-19 Pandemic in North American Country Markets- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Fabre-Kramer Pharmaceuticals, Inc.
- Bioasis Technologies, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America blood brain barrier technologies market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America blood brain barrier technologies market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the blood brain barrier technologies market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution